Suppression of MMQ cells by fulvestrant: possible mechanism of action and potential application for bromocriptine-resistant prolactinomas
Authors:
- Songbai GuiSGSongbai Gui
- Yazhuo ZhangYZYazhuo Zhang
- 1 May 2013
- journal article
- research article
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 20 (5) , 721-725
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Effects of an estrogen receptor antagonist on proliferation, prolactin secretion and growth factor expression in the MMQ pituitary prolactinoma cell lineJournal of Clinical Neuroscience, 2011
- Dopamine agonist–resistant prolactinomasJournal of Neurosurgery, 2011
- Wnt signaling in estrogen-induced lactotroph proliferationJournal of Cell Science, 2011
- Estrogen Receptors and Signaling Pathways in Lactotropes and SomatotropesNeuroendocrinology, 2010
- Identification of Wnt family inhibitors: A pituitary tumor directed whole genome approachMolecular and Cellular Endocrinology, 2010
- Reversal of hypogonadotropic hypogonadism with tamoxifen in a patient with hyperprolactinemia resistant to dopamine agonistsFertility and Sterility, 2005
- Convergence of Wnt, ß-Catenin, and Cadherin PathwaysScience, 2004
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Volume of Pituitary MacroadenomasJournal of Computer Assisted Tomography, 1992
- Effect of Tamoxifen Administration on Prolactin Release by Invasive Prolactin-Secreting Pituitary AdenomasNeuroendocrinology, 1982